FDMT vs FULC

4D Molecular Therapeutics, Inc. vs Fulcrum Therapeutics, Inc. — Valuation Comparison 2026

FDMT

Biotechnology
4D Molecular Therapeutics, Inc.
Quality
7.1
out of 10
Value Trap
24
SAFE
Price
$8.97
Last close
Models
9/13
Active
VS

FULC

Biotechnology
Fulcrum Therapeutics, Inc.
Quality
6.5
out of 10
Value Trap
18
SAFE
Price
$6.82
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType FDMT Fair ValueFDMT Upside FULC Fair ValueFULC Upside
Bayesian DCF Intrinsic $3.01 -66.5% $2.23 -67.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $4.34 -50.0% $0.36 -94.5%
Dynamic NAV Asset-Based $8.24 -8.1% $3.71 -45.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for FDMT vs FULC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

FDMT vs FULC — Which Stock Is More Undervalued?

FDMT scores higher with a 7.1/10 quality rating vs FULC's 6.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing 4D Molecular Therapeutics, Inc. (FDMT) and Fulcrum Therapeutics, Inc. (FULC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

FDMT currently trades at $8.97 with a QOC of 7.1/10, while FULC trades at $6.82 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).